Fidson Healthcare Plc shares soared 37% in early January, reaching ₦69 on the NGX.
The stock opened the year at ₦50, and investors traded over 10 million shares already.
Strong January Rally
This surge follows a remarkable 231.5% gain in 2025, as investors responded to strong financial results.
In Q3 2025, the company earned a pre-tax profit of ₦2.9 billion, slightly above ₦2.87 billion last year.
Moreover, for nine months, Fidson grew pre-tax profit 131.7% to ₦11.9 billion, driven by rising revenue.
Robust Earnings Growth
Q3 revenue reached ₦30.4 billion, up 35.4% compared with the same quarter in 2024.
Higher sales in ethical and OTC pharmaceuticals drove this growth, with Nigeria contributing 99.6% of revenue.
Although production and input costs rose, the company increased gross profit to ₦12.5 billion, marking a 31.2% year-on-year improvement.
Read Also: Fortis Rakes In ₦5Bn Profit On Property Revaluation In 2024
Meanwhile, higher administrative, selling, and financing costs slightly limited gains, yet operating profit continued growing.
Strategic Expansion
In December 2025, Fidson launched a ₦21 billion Rights Issue, offering 600 million shares at ₦35 each.
The company will use proceeds to expand manufacturing, develop products, and grow across Africa, backed by Ohara.
Japan’s Ohara Pharmaceutical provides technical support, helping Fidson strengthen local production capacity.
Consequently, investors responded positively to earnings growth and strategic market expansion plans.
The Rights Issue ranks among the largest recent healthcare capital market deals on the NGX.
Early January trading reflects confidence in Fidson’s strategy, despite currency fluctuations and exchange losses.
If executed successfully, Fidson could build on the historic 231.5% stock gain recorded in 2025.
